HIV-1 assembly and budding as targets for drug discovery

Current Opinion in Investigational Drugs

Volumn 6, Issue 2, 2005, Pages 148-154

  Li, Feng ^a   Wild, Carl ^a  

^a Panacos Pharmaceuticals   (United States)

Author keywords

Assembly; Budding; Drug; HIV 1; Target

Indexed keywords

3 O (3,3 DIMETHYLSUCCINYL)BETULIC ACID; ACH 0100703; ANTIRETROVIRUS AGENT; AZOFORMAMIDE; BETULIC ACID; BORONIC ACID DERIVATIVE; CAP 1; CAPSID PROTEIN; DIMETHYL SUCCINYL BETULINIC ACID; GAG PROTEIN; GLYCYLPROLYLGLYCINE; MATRIX PROTEIN; MPI 49839; N (3 CHLORO 4 METHYLPHENYL) N' [2 [[[5 [(DIMETHYLAMINO)METHYL] 2 FURYL]METHYL]SULFANYL]ETHYL]UREA; NUCLEOCAPSID PROTEIN; PROTEIN P6; PROTEIN SPACER PEPTIDE 1; PROTEIN SPACER PEPTIDE 2; PS 273; TRIPEPTIDE; TUMOR SUSCEPTIBILITY GENE 101 PROTEIN; UBIQUITIN; UNCLASSIFIED DRUG; UREA DERIVATIVE; VIRUS PROTEIN;

BUDDING; CLINICAL TRIAL; DRUG INHIBITION; DRUG MECHANISM; DRUG TARGETING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPID RAFT; MYRISTYLATION; PROTEIN PROTEIN INTERACTION; REVIEW; VIRUS ASSEMBLY; VIRUS CAPSID; VIRUS NUCLEOCAPSID; VIRUS REPLICATION; ZINC FINGER MOTIF; BIOSYNTHESIS; DRUG EFFECT; GROWTH, DEVELOPMENT AND AGING; PHYSIOLOGY;

CAPSID; GENE PRODUCTS, GAG; HIV-1; HUMANS; NUCLEOCAPSID; VIRUS ASSEMBLY;

EID: 15744370269     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. Panel on Clinical Practices for the Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Department of Health and Human Services (2000):35-36.
2. Gulick RM: Current status of new antiretroviral drugs in development. Topics in HIV medicine. International AIDS Society - US4(2002)10(4):14-19.
3. Freed EO: HIV-1 Gag proteins: Diverse functions in the virus life cycle. Virology (1998) 251(1):1-15. This review describes what is known and what remains to be learned about the role of Gag and cellular factors in retroviruses assembly and budding.
4. Gottlinger HG: The HIV-1 assembly machine. AIDS (2001) 15(Suppl 5):13-20. This is an updated comprehensive review of HIV-1 Gag and the cellular factors driving HIV-1 assembly/budding.
5. Morita E, Sundquist WI: Retrovirus budding. Annu Rev Cell Dev Biol (2004) 20:395-425. This review details the latest research on the p6 L domain and its cellular partners in the retrovirus budding process.
6. Garnier L, Bowzard JB, Wills JW: Recent advances and remaining problems in HIV assembly. AIDS (1998) 12(Suppl A):5-16.
7. Ott D, Coren L, Gagliardi T: HIV-1 particle production requires the presence of either a basic region within MA or the NC domain - implication for an RNA requirement in virion assembly. Cold Spring Harbor Laboratory Retroviruses Meeting, New York, NY, USA (2004): Abs 115.
8. Hill CP, Worthylake D, Bancroft DP, Christensen AM, Sundquist WI: Crystal structures of the trimeric human immunodeficiency virus type 1 matrix protein: Implications for membrane association and assembly. Proc Natl Acad Sci USA (1996) 93(7):3099-3104.
9. Tang C, Loeliger E, Luncsford P, Kinde I, Beckett D, Summers MF: Entropic switch regulates myristate exposure in the HIV-1 matrix protein. Proc Natl Acad Sci USA (2004) 101(2):517-522.
10. Murakami T, Freed EO: The long cytoplasmic tail of gp41 is required in a cell type-dependent manner for HIV-1 envelope glycoprotein incorporation into virions. Proc Natl Acad Sci USA (2000) 97(1):343-348.
11. Worthylake DK, Wang H, Yoo S, Sundquist Wl, Hill CP: Structures of the HIV-1 capsid protein dimerization domain at 2.6 Å resolution. Acta Crystallogr D Biol Crystallogr (1999) 55(1):85-92.
12. Li S, Hill CP, Sundquist WI, Finch JT: Image reconstructions of helical assemblies of the HIV-1 CA protein. Nature (2000) 407(6802):409-413.
13. Tang C, Ndassa Y, Summers MF: Structure of the N-terminal 283-residue fragment of the immature HIV-1 Gag polyprotein. Nat Struct Biol (2002) 9(7):537-543. This paper provides a description of the conformational differences in the capsid protein pre- and post-cleavage, and the authors propose this conformational rearrangement as an HIV-1 drug target.
14. Franke EK, Yuan HE, Luban J: Specific incorporation of cyclophilin A into HIV-1 virions. Nature (1994) 372(6504):359-362.
15. Thali M, Bukovsky A, Kondo E, Rosenwirth B, Walsh CT, Sodroski J, Gottlinger HG: Functional association of cyclophilin A with HIV-1 virions. Nature (1994) 372(6504):363-365.
16. Braaten D, Luban J: Cyclophilin A regulates HIV-1 infectivity, as demonstrated by gene targeting in human T cells. EMBO J (2001) 20(6):1300-1309.
17. Saphire AC, Bobardt MD, Gallay PA: Cyclophilin A plays distinct roles in human immunodeficiency virus type 1 entry and post-entry events, as revealed by spinoculation. J Virol (2002) 76(9):4671-4677.
18. Rein A, Henderson LE, Levin JG: Nucleic-acid-chaperone activity of retroviral nucleocapsid proteins: Significance for viral replication. Trends Biochem Sci (1998) 23(8):297-301.
19. Berkowitz R, Fisher J, Goff SP: RNA packaging. Curr Top Microbiol Immunol (1996) 214:177-218.
20. Muriaux D, Mirro J, Harvin D, Rein A: RNA is a structural element in retrovirus particles. Proc Natl Acad Sci USA (2001 ) 98(9):5246-5251. This paper demonstrates that Gag is able to interact non-spedfically with RNA to drive retrovirus assembly and release, using either viral or cellular RNA as a scaffold.
21. Campbell S, Rein A: In vitro assembly properties of human immunodeficiency virus type 1 Gag protein lacking the p6 domain. J Virol (1999) 73(3):2270-2279.
22. Feng YX, Li T, Campbell S, Rein A: Reversible binding of recombinant human immunodeficiency virus type 1 gag protein to nucleic acids in virus-like particle assembly in vitro. J Virol (2002) 76(22):11757-11762.
23. Ma YM, Vogt VM: Rous sarcoma virus Gag protein-oligonucleotide interaction suggests a critical role for protein dimer formation in assembly. J Virol (2002) 76(11):5452-5462.
24. Freed EO, Ross SR: Retroviruses 2004: Review of the 2004 Cold Spring Harbor Retroviruses conference. Retrovirology (2004) 1(1):25.
25. Gottlinger HG, Dorfman T, Sodroski JG, Haseltine WA: Effect of mutations affecting the p6 Gag protein on human immunodeficiency virus particle release. Proc Natl Acad Sci USA (1991) 88(8):3195-3199.
26. Huang M, Orenstein JM, Martin MA, Freed EO: p6 Gag is required for particle production from full-length human immunodeficiency virus type 1 molecular clones expressing protease. J Virol (1995) 69(11):6810-6818.
27. Strack B, Calistri A, Craig S, Popova E, Gottlinger HG: AIP1/ALIX is a binding partner for HIV-1 p6 and EIAV p9 functioning in virus budding. Cell (2003) 114(6):689-699. The authors of this paper and reference [45•] demonstrate that AIP-1 binds p6 and, together with Tsg101, is crucially involved in orchestrating HIV-1 budding.
28. Freed EO: Viral late domains. J Virol (2002) 76(10):4679-4687. This review summarizes current knowledge concerning viral L domain function and presents recent progress in understanding the roles of cellular partners in viral assembly/budding.
29. Luban J: HIV-1 and Ebola virus: The getaway driver nabbed. Nat Med (2001) 7(12):1278-1280.
30. Paxton W, Connor Rl, Landau NR: Incorporation of Vpr into human immunodeficiency virus type 1 virions: Requirement for the p6 region of Gag and mutational analysis. J Virol (1993) 67(12):7229-7237.
31. Pettit SC, Moody MD, Wehbie RS, Kaplan AH, Nantermet PV, Klein CA, Swanstrom R: The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions. J Virol (1994) 68(12):8017-8027.
32. Krausslich HG, Facke M, Heuser AM, Konvalinka J, Zentgraf H: The spacer peptide between human immunodeficiency virus capsid and nucleocapsid proteins is essential for ordered assembly and viral infectivity. J Virol (1995) 69(6):3407-3419.
33. Accola MA, Hoglund S, Gottlinger HG: A putative α-helical structure which overlaps the capsid-p2 boundary in the human immunodeficiency virus type 1 Gag precursor is crucial for viral particle assembly. J Virol (1998) 72(3):2072-2078.
34. Newman JL, Butcher EW, Patel DT, Mikhaylenko Y, Summers MF: Flexibility in the P2 domain of the HIV-1 Gag polyprotein. Protein Sci (2004) 13(8):2101-2107.
35. Wiegers K, Rutter G, Kottler H, Tessmer U, Hohenberg H, Krausslich HG: Sequential steps in human immunodeficiency virus particle maturation revealed by alterations of individual Gag polyprotein cleavage sites. J Virol (1998) 72(4):2846-2854.
36. Gross I, Hohenberg H, Wilk T, Wiegers K, Grattinger M, Muller B, Fuller S, Krausslich HG: A conformational switch controlling HIV-1 morphogenesis. EMBO J (2000) 19(1):103-113. This is the first paper to report the effect of the SP1 peptide on HIV-1 morphogenesis in an in vitro assembly system. The compelling biological, genetic and morphological evidence suggests that the SP1 peptide acts as a molecular switch to control a conformational rearrangement that is required for virus maturation.
37. Kaye JF, Lever AM: Nonreciprocal packaging of human immunodeficiency virus type 1 and type 2 RNA: A possible role for the p2 domain of Gag in RNA encapsidation. J Virol (1998) 72(7):5877-5885.
38. Hill MK, Shehu-Xhilaga M, Crowe SM, Mak J: Proline residues within spacer peptide p1 are important for human immunodeficiency virus type 1 infectivity, protein processing, and genomic RNA dimer stability. J Virol (2002) 76(22):11245-11253.
39. Ott DE, Coren LV, Johnson DG, Kane BP, Sowder RC, Kim YD, Fisher RJ, Zhou XZ, Lu KP, Henderson LE: Actin-binding cellular proteins inside human immunodeficiency virus type 1. Virology (2000) 266(1):42-51.
40. Zimmerman C, Klein KC, Kiser PK, Singh AR, Firestein BL, Riba SC, Lingappa JR: Identification of a host protein essential for assembly of immature HIV-1 capsids. Nature (2002) 415(6867):88-92.
41. Freed EO: The HIV-TSG101 interface: Recent advances in a budding field. Trends Microbiol (2003) 11(2):56-59.
42. Vogt VM: Ubiquitin in retrovirus assembly: Actor or bystander? Proc Natl Acad Sci USA (2000) 97(24):12945-12947.
43. Garrus JE, von Schwedler UK, Pomillos OW, Morham SG, Zavitz KH, Wang HE, Wettstein DA, Stray KM, Cote M, Rich RL, Myszka DG et al: Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding. Cell (2001) 107(1):55-65. This paper reports that Tsg101 depletion inhibited HIV-1 replication at a late step in the budding process and that re-introduction of Tsg101 rescues HIV-1 budding. In addition, dominant-negative mutant Vps4 proteins that block vacuolar protein sorting also arrest HIV-1 budding. Their results provide a proof-of-concept in that Tsg101/Vps proteins are involved in HIV assembly/budding.
44. Ferez OD, Nolan GP: Resistance is futile: Assimilation of cellular machinery by HIV-1. Immunity (2001) 15(5):687-690. This review provides a detailed analysis of ubiquitin in retrovirus assembly. The authors also discuss in detail how host-dependent cellular processes could serve as targets for inhibitors of virus replication with a focus on assembly/budding.
45. von Schwedler UK, Stuchell M, Muller B, Ward DM, Chung HY, Morita E, Wang HE, Davis T, He GP, Cimbora DM, Scott A et al: The protein network of HIV budding. Cell (2003) 114(6):701-713. The authors of this paper and reference [27•] demonstrate that AIP-1 binds p6 and, together with Tsg101, is crucially involved in orchestrating HIV-1 budding.
46. Ott DE, Coren LV, Chertova EN, Gagliardi TD, Schubert U: Ubiquitination of HIV-1 and MuLV Gag. Virology (2000) 278(1):111-121.
47. Schubert U, Ott DE, Chertova EN, Welker R, Tessmer U, Princiotta MF, Bennink JR, Krausslich HG, Yewdell JW: Proteasome inhibition interferes with gag polyprotein processing, release, and maturation of HIV-1 and HIV-2. Proc Natl Acad Sci USA (2000) 97(24):13057-13062. This paper provides the first direct evidence for the role of ubiquitin in HIV-1 budding. The researchers used proteasome inhibitors to treat cells transfected with an HIV-1 proviral DNA construct. This treatment reduced intracellular levels of free ubiquitin by trapping conjugated ubiquitin inside the blocked proteasomes, preventing it from being recycled. The reduction in ubiquitin content resulted in a block to HIV-1 particle release and a significant reduction in viral infectivity.
48. Strack B, Calistri A, Accola MA, Palu G, Gottlinger HG: A role for ubiquitin ligase recruitment in retrovirus release. Proc Natl Acad Sci USA (2000) 97(24):13063-13068.
49. Strack B, Calistri A, Gottlinger HG: Late assembly domain function can exhibit context dependence and involves ubiquitin residues implicated in endocytosis. J Virol (2002) 76(11):5472-5479.
50. VerPlank L, Bouamr F, LaGrassa TJ, Agresta B, Kikonyogo A, Leis J, Carter CA: Tsg101, a homologue of ubiquitin-conjugating (E2) enzymes, binds the L domain in HIV type 1 Pr55(Gag). Proc Natl Acad Sci USA (2001) 98(14):7724-7729.
51. Martin-Serrano J, Zang T, Bieniasz PD: HIV-1 and Ebola virus encode small peptide motifs that recruit Tsg101 to sites of particle assembly to facilitate egress. Natl Med (2001) 7(12):1313-1319.
52. Demirov DG, Ono A, Orenstein JM, Freed EO: Overexpression of the N-terminal domain of TSG101 inhibits HIV-1 budding by blocking late domain function. Proc Natl Acad Sci USA (2002) 99(2):955-960.
53. Katzmann DJ, Babst M, Emr SD: Ubiquitin-dependent sorting into the multivesicular body pathway requires the function of a conserved endosomal protein sorting complex, ESCRT-I. Cell (2001) 106(2):145-155.
54. Pomillos O, Higginson DS, Stray KM, Fisher RD, Garrus JE, Payne M, He GP, Wang HE, Morham SG, Sundquist WI: HIV Gag mimics the Tsg101-recruiting activity of the human Hrs protein. J Cell Biol (2003) 162(3):425-434.
55. Nguyen DH, Hildreth JE: Evidence for budding of human immunodeficiency virus type 1 selectively from glycolipid-enriched membrane lipid rafts. J Virol (2000) 74(7):3264-3272. This is the first paper investigating the role of lipid rafts in HIV-1 budding and provides some insights into the prevention of HIV-1 infection by targeting lipid rafts.
56. Lindwasser OW, Resh MD: Multimerization of human immunodeficiency virus type 1 Gag promotes its localization to barges, raft-like membrane microdomains. J Virol (2001) 75(17):7913-7924.
57. Ono A, Freed EO: Plasma membrane rafts play a critical role in HIV-1 assembly and release. Proc Natl Acad Sci USA (2001) 98(24):13925-13930.
58. Goebel FD, Hemmer R, Schmit JC, Bogner JR, de Clercq E, Witvrouw M, Pannecouque C, Valeyev R, Vandevelde M, Margery H, Tassignon JP: Phase VII dose escalation and randomized withdrawal study with add-on azodicarbonamide in patients failing on current antiretroviral therapy. AIDS (2001) 15(1):33-45.
59. Hou X, Zhao Y, Fabrycki J, Liu D, Marlor C, Thoma C, Yang W, Song Y, Bradbury B, Rice W, Deshpande M et at. A novel HIV inhibitor that targets the nucleocapsid protein. ICAAC (2002) 42:Abs H-185.
60. Hoglund S, Su J, Reneby SS, Vegvari A, Hjerten S, Sintom IM, Foster H, Wu YP, Nystrom I, Vahlne A: Tripeptide interference with human immunodeficiency virus type 1 morphogenesis. Antimicrob Agents Chemother (2002) 46(11):3597-3605.
61. Su J, Andersson E, Horal P, Naghavi MH, Palm A, Wu YP, Eriksson K, Jansson M, Wigzell H, Svennerholm B, Vahlne A: The nontoxic tripeptide glycyl-prolyl-glycine amide inhibits the replication of human immunodeficiency virus type 1. J Hum Virol (2001) 4(1):1-7.
62. Spira J, Nyman L, Goobar-Larsson L, Vahlne A: Pharmacodynamic anti-HIV response for 12 hours after single dose of the tripeptide GPG-NH2 in healthy volunteers. International AIDS Society Conference on HIV Pathogenesis and Treatment, Buenos Aires, Argentina (2001) 1: Abs 250.
63. Tang C, Loeliger E, Kinde I, Kyere S, Mayo K, Barklis E, Sun Y, Huang M, Summers MF: Antiviral inhibition of the HIV-1 capsid protein. J Mol Biol (2003) 327(5): 1013-1020.
64. Li F, Goila-Gaur R, Salzwedel K, Kilgore NR, Reddick M, Matallana C, Castillo A, Zoumplis D, Martin DE, Orenstein JM, Allaway GP et ah PA-457: A potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing. Proc Natl Acad Sci USA (2003) 100(23):13555-13560. This paper and reference [65•] report two independent studies revealing that the potent, small molecule HIV-1 inhibitor PA-457 blocks a late step in Gag processing, involving conversion of the capsid precursor (CA-SP1) to mature CA, and that PA-457 represents a novel class of anti-HIV compounds, termed maturation inhibitors that exploit a previously unidentified viral target.
65. Zhou J, Yuan X, Dismuke D, Forshey BM, Lundquist C, Lee KH, Aiken C, Chen CH: Small-molecule inhibition of human immunodeficiency virus type 1 replication by specific targeting of the final step of virion maturation. J Virol. (2004) 78(2):922-929. This paper and reference [64•] report two independent studies revealing that the potent, small molecule HIV-1 inhibitor PA-457 blocks a late step in Gag processing, involving conversion of the capsid precursor (CA-SP1) to mature CA, and that PA-457 represents a novel class of anti-HIV compounds, termed maturation inhibitors that exploit a previously unidentified viral target.
66. Zhou J, Chen CH, Aiken C: The sequence of the CA-SP1 junction accounts for the differential sensitivity of HIV-1 and SIV to the small molecule maturation inhibitor 3-O-{3′,3′-dimethylsuccinyl}-betulinic acid. Retrovirology (2004) 1(1):15.
67. Martin DE, Smith PC, Wild CT, Allaway GP: In vitro and in vivo disposition of PA-457, a novel inhibitor of HIV-1 maturation. International AIDS Conference (2004) 15: Abs WePeA5644.
68. Ott, D, Tessmer U, Lucas K, Hohenberg H, Princiotta MF, Bennink JR, Yewdell JW, Adams J, Weich N, Stahlhennig C, Schubert U: Anti-retroviral effect of proteasome inhibitors in vitro and in vivo. Cold Spring Harbor Laboratory Retroviruses meeting, New York, NY, USA (2002): AbS 365.
69. Myriad Genetics. Company Web Site (2004). http://www.myriad.com.
70. Lindwasser OW, Resh MD: Myristoylation as a target for inhibiting HIV assembly: Unsaturated fatty acids block viral budding. Proc Natl Acad Sci USA (2002) 99(20):13037-13042.
71. Liao Z, Cimakasky LM, Hampton R, Nguyen DH, Hildreth JE: Lipid rafts and HIV pathogenesis: Host membrane cholesterol is required for infection by HIV type 1. AIDS Res Hum Retroviruses (2001) 17(11):1009-1019.